Sensus Healthcare (NASDAQ:SRTS) Now Covered by Analysts at Alliance Global Partners

Alliance Global Partners initiated coverage on shares of Sensus Healthcare (NASDAQ:SRTS) in a report issued on Friday, Marketbeat.com reports. The firm issued a buy rating and a $7.50 target price on the stock.

SRTS has been the subject of a number of other reports. Maxim Group decreased their price objective on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.88.

Sensus Healthcare Stock Performance

NASDAQ SRTS traded down $0.03 during trading on Friday, reaching $4.25. The company’s stock had a trading volume of 40,750 shares, compared to its average volume of 115,366. The business’s fifty day moving average price is $4.54 and its 200-day moving average price is $3.89. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $5.92. The firm has a market cap of $69.96 million, a price-to-earnings ratio of -9.04 and a beta of 1.22.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.10). The business had revenue of $4.94 million for the quarter, compared to analyst estimates of $8.35 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%. As a group, sell-side analysts forecast that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Divisadero Street Capital Management LP raised its stake in shares of Sensus Healthcare by 459.4% during the 2nd quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company’s stock worth $1,539,000 after buying an additional 266,635 shares in the last quarter. Greenline Wealth Management LLC acquired a new position in Sensus Healthcare during the fourth quarter worth $513,000. Rothschild Wealth LLC purchased a new position in Sensus Healthcare in the fourth quarter worth $500,000. Pacific Ridge Capital Partners LLC raised its position in Sensus Healthcare by 21.8% in the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after acquiring an additional 125,245 shares in the last quarter. Finally, Ingalls & Snyder LLC acquired a new stake in Sensus Healthcare in the fourth quarter valued at $219,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.